MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 778 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. reduced its stake in Alnylam Pharmaceuticals by 5.3%, now owning 13,953 shares valued at $3,764,000 as of its recent SEC filing.
• Institutional investors are actively trading Alnylam stocks, with Vanguard Group Inc. increasing its holdings by 2.5% and other investors significantly boosting their stakes.
• Alnylam Pharmaceuticals recently reported a positive earnings surprise for the last quarter, with total revenue of $773.69 million, surpassing analysts' expectations and reflecting a 17.3% year-over-year growth.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 13,953 shares of the biopharmaceutical company's stock after selling 778 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Alnylam Pharmaceuticals were worth $3,764,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in ALNY. Brighton Jones LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $243,000. Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals by 66.3% during the fourth quarter. Cetera Investment Advisers now owns 4,770 shares of the biopharmaceutical company's stock worth $1,122,000 after acquiring an additional 1,902 shares during the period. Focus Partners Wealth grew its holdings in shares of Alnylam Pharmaceuticals by 245.1% in the fourth quarter. Focus Partners Wealth now owns 4,427 shares of the biopharmaceutical company's stock valued at $1,042,000 after purchasing an additional 3,144 shares during the period. OMERS ADMINISTRATION Corp lifted its position in Alnylam Pharmaceuticals by 20.4% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 5,252 shares of the biopharmaceutical company's stock valued at $1,236,000 after buying an additional 891 shares during the last quarter. Finally, Nissay Asset Management Corp Japan ADV grew its position in shares of Alnylam Pharmaceuticals by 2.1% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 15,947 shares of the biopharmaceutical company's stock worth $3,795,000 after buying an additional 324 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Pushkal Garg sold 1,455 shares of the company's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total transaction of $666,986.55. Following the completion of the transaction, the executive vice president directly owned 20,221 shares in the company, valued at approximately $9,269,508.61. This represents a 6.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of the business's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the sale, the director directly owned 16,804 shares in the company, valued at approximately $7,561,800. This represents a 40.10% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 75,594 shares of company stock valued at $33,968,256. Corporate insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ:ALNY traded down $4.75 during mid-day trading on Monday, reaching $461.14. 910,054 shares of the stock were exchanged, compared to its average volume of 1,109,281. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $484.21. The company has a market cap of $60.45 billion, a P/E ratio of -186.70 and a beta of 0.32. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The stock's 50 day simple moving average is $404.20 and its 200-day simple moving average is $319.41.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. During the same quarter in the prior year, the business posted ($0.13) EPS. The business's revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

ALNY has been the subject of several recent analyst reports. Evercore ISI raised their price target on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an "outperform" rating in a report on Thursday. Truist Financial began coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $385.00 price target on the stock. Bank of America increased their price objective on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a "buy" rating in a report on Friday, July 11th. Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Finally, UBS Group boosted their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a report on Friday, August 1st. Twenty-three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $421.28.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.